Novavax (NVAX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$413.8M

Revenue (quarter)

$56.7M

Revenue growth (year over year)

−76.30%

Gross profit (trailing twelve months)

$325.3M

Gross margin

78.60%

Net income (trailing twelve months)

−$247.7M

Net income (quarter)

−$53.4M

Net income growth (year over year)

−150.12%

Net margin

−59.87%

Return on equity

—

EPS (trailing twelve months)

−$1.53

Book value per share

−$1.16

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

119.96%

Payout ratio

—

Dividend yield

—

Company profile

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

• Is Novavax (NVAX) profitable?

  No. Novavax reported a net loss of $247.7M over the trailing twelve months.

• How much revenue does Novavax (NVAX) make?

  Novavax generated $413.8M in revenue over the trailing twelve months, down 76.30% year over year.

• How do I buy stock in Novavax (NVAX)?

  NVAX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.